Nextleaf Solutions Ltd (CSE:OILS) updated Tuesday on its rapid emulsion technology, telling investors it had now completed successful scale trials for a variety of products manufactured with the firm's patent-pending technology.
Nextleaf is the first public company to be issued US patents for industrial-scale extraction and distillation of cannabinoids and highlighted in the release that it enjoys a pending to issued patent allowance success rate of 100%, with over 40 issued patents globally so far.
Emma Andrews, the firm's director of marketing, said the group's rapid emulsion tech provided "exceptional stability when developing a wide range of infused products such as edibles and beverages."
She added: "Being able to accommodate different flavors, potency, and pH values - with ease - provides greater flexibility and speed-to-market advantages during product development."
Ten years of collective R&D has resulted in a proprietary delivery system that has been adapted to cannabis, increasing bioavailability through micro and nano emulsification to deliver rapid onset of THC, CBD, and other cannabinoids, the firm said.
"Complimenting Nextleaf's demonstrated excellence in efficiently processing high purity distillate, Rapid Emulsion Technology by OILS will be available to B2B partners as an additional service alongside toll processing, bulk ingredient sales, IP licensing, and R&D," the group told investors.
Nextleaf is Canada's most innovative cannabis extractor, developing technology for extracting and distilling cannabinoids. It provides extraction services and wholesale of THC and CBD oils through Nextleaf Labs, a Health Canada licensed standard processor.
The group’s proprietary closed-loop extraction plant in Metro Vancouver has a design capacity to process 600 kg per day of dried cannabis biomass into distilled oils.
Contact the author at giles@proactiveinvestors.com
